TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01842581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be administered per the dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be administered per the dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Laculose will be administered per the schedule specified in the respective arm.
Study: NCT03738319

Intervention type: GENETIC
Intervention: Sequencing of miRNA/lncRNA
Description: Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)

Intervention type: GENETIC
Intervention: Sequencing of miRNA/lncRNA
Description: Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
Study: NCT03368014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lyrics-writing and singing show
Description: Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony.
Study: NCT01020708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalamine
Description: 4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTH12-1:4
Description: ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTH12-2:4
Description: ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
Study: NCT01656369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I: delorme operation only.
Description: A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
Study: NCT04627168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive, surface electrical stimulation device, DS5 Digitimer
Description: Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive, surface electrical stimulation device, DS5 Digitimer
Description: Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.
Study: NCT02350400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEBIRI
Description: DEBIRI TACE
Study: NCT01656369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delorme operation with post anal repair
Description: In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
Study: NCT02159677

Intervention type: DEVICE
Intervention: EIM Measurements

Intervention type: DEVICE
Intervention: EIM Measurements

Intervention type: DEVICE
Intervention: EIM Measurements

Intervention type: DEVICE
Intervention: EIM Measurements
Study: NCT02358655

Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective review of OAC prescription

Intervention type: OTHER
Group type: OTHER
Intervention: Prescription of OAC in ED

Intervention type: OTHER
Group type: OTHER
Intervention: Prescription of OAC in ED

Intervention type: OTHER
Group type: OTHER
Intervention: Community AF clinic
Study: NCT01308151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other
Description: No interventions other than the culturally adapted manualised cognitive behavioral therapy
Study: NCT00620672

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: omega 3 fatty acids
Description: The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: vegetable oil
Description: The supplement is a dietary supplement of vegetable oil as a placebo
Study: NCT03316755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Exposure to pamphlet
Study: NCT02976194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
Study: NCT04754568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality instructional design
Description: 60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
Study: NCT03783611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0.
Description: eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
Study: NCT04262713

Intervention type: OTHER
Group type: OTHER
Intervention: Radiographs
Description: Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh\>60, Long neck stem, Varus; DEVANE score ≥ 4)
Study: NCT01735708

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIVPASS

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Study: NCT02190305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplo HBc/HIV/HCV and Reveal HBsAg
Description: All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
Study: NCT02784015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study: NCT00650520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
Description: 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
Description: 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study: NCT01971216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Study: NCT03288194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time Management
Study: NCT04399954

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketoflo
Description: Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
Study: NCT00542737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Educational Program
Description: Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Educational Program
Description: Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
Study: NCT00964847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga exercise program
Description: Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga exercise program
Description: Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure education/walking program
Description: The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure education/walking program
Description: The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
Study: NCT03883334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metisoprinol
Description: Immunodulator
Study: NCT02716701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wristband activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wristband activity tracker
Study: NCT01881022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosexual Intervention
Description: Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
Study: NCT03542851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentetrazol (PTZ)
Description: BTD-001 is an oral capsule of PTZ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentetrazol (PTZ)
Description: BTD-001 is an oral capsule of PTZ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be presented as oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be presented as oral capsule.
Study: NCT02552251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hormonal balance measurements

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hormonal balance measurements

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hormonal balance measurements

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: metabolic balance measurements

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: metabolic balance measurements

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: metabolic balance measurements

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone balance measurements

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone balance measurements

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone balance measurements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality of life assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality of life assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Study: NCT01690351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Oral dispersion TS formulation- fasted
Study: NCT00118534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care for Smoking Cessation in PTSD patients
Description: Smoking cessation therapy is integrated with PTSD therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
Study: NCT01690351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Capsules TS formulation- fasted
Study: NCT00267046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin (Doxorubicin)
Description: 30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adriamycin (Doxorubicin)
Description: 30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ifosfamide
Description: 2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
Study: NCT02005172

Intervention type: DEVICE
Group type: OTHER
Intervention: Alivecor monitor and 14 day event monitor
Description: Alivecor monitor and 14 day event monitor
Study: NCT03927287

Intervention type: DIAGNOSTIC_TEST
Intervention: Free PSA ratio test in patients after definitive treatment for localized prostate cancer
Description: Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
Study: NCT00267046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: 2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 120 mg/m\^2 on day 0, for patients receiving the AP Regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 120 mg/m\^2 on day 0, for patients receiving the AP Regimen.
Study: NCT04218578

Intervention type: DIAGNOSTIC_TEST
Intervention: speckle tracking analysis of transthoracic echocardiogram
Description: analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination

Intervention type: DIAGNOSTIC_TEST
Intervention: speckle tracking analysis of transthoracic echocardiogram
Description: analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination
Study: NCT01730157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: Given via hepatic arterial infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02593292

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROSPERO
Description: The intervention is carried out in 3 steps:~1. At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~2. During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~3. The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
Study: NCT03266939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: 10 mg acute administration of lorcasein
Study: NCT00103142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: falimarev
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: falimarev
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inalimarev
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inalimarev
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given subcutaneously and intradermally
Study: NCT03731884

Intervention type: OTHER
Intervention: Time from the onset of symptoms to PCI
Description: Patients will be divided in two groups according to the time from the onset of symptoms to PCI

Intervention type: OTHER
Intervention: Time from the onset of symptoms to PCI
Description: Patients will be divided in two groups according to the time from the onset of symptoms to PCI
Study: NCT01396707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin+XELOX
Description: Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~* Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~* Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Oxaliplatin 130 mg/m2 i.v. on day 1
Study: NCT02601742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zinc group
Description: Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Pedialyte oral electrolyte solution, 330 ml per day for 7 days
Study: NCT02208947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumer financial incentive
Description: Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREPARE
Description: PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE
Description: PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library).